The article reports on draft guidance of National Institute for Health and Care Excellence (NICE) which includes recommendation on drugs gemcitabine, paclitaxel and pegylated liposomal doxorubicin for the treatment of recurrent ovarian cancer.doi:10.1007/s40274-015-2662-0None...
“This draft guidance is timely and important. Criticism of the accelerated approval pathway has increased as multiple drugs approved under this mechanism remain on the market without completion of confirmatory studies.” wrote Lori J. Pierce, MD, FASTRO, FASCO, then-Chair of the B...